Research shows limited impact of ban on flavored e-cigarettes

Dec.01.2022
Research shows limited impact of ban on flavored e-cigarettes
The US ban on flavored e-cigarettes has had limited effectiveness, as users turn to alternative products and flavors.

On February 6, 2020, the United States Food and Drug Administration banned the sale of several flavors of electronic cigarettes, with some significant exceptions.


According to a survey published in the journal "Tobacco Control," out of 3500 adult users of electronic cigarettes who were surveyed, less than 5% of them stopped using electronic cigarettes due to the ban on flavored e-cigarettes. The remaining respondents switched to other types or flavors of electronic cigarettes or other tobacco products that were not covered by the ban.


More and more literature suggests that the flavorings in e-cigarettes can cause harm when inhaled, making a ban on these flavorings reasonable, according to tobacco research expert and Professor of Public Health Sciences and Community Center Deborah J. Ossip. "But bans don't seem to be effective. People, including young people, can still access flavored products and are still using them," she added. This statement was made at the University of Rochester Medical Center's Department of Public Health and Prevention.


According to Dongmei Li, the lead author of the study and associate professor of clinical and translational research, obstetrics and gynecology, and public health sciences, a significant part of the problem is that the ban does not cover newer products such as disposable e-cigarette pods and e-cigarette pods that use canisters instead of cartridges/boxes.


Other forms of flavored electronic cigarettes, particularly disposable ones, have become very popular after FDA policies were implemented," said Li. "The FDA's policies did not prohibit products with mint or tobacco flavors - our research indicates that many people switched to mint-flavored e-cigarettes after the ban. It seems that many people find menthol to be a favorable taste.


According to this study, nearly 30% of the survey respondents switched to canned or disposable flavored e-cigarettes, and another 30% switched to mint or tobacco flavored pods. Some reported turning to traditional tobacco products: 14% switched to combustible products like cigarettes, and 5% switched to smokeless products such as chewing or dipping tobacco. Less than 5% of respondents stopped using e-cigarettes after the FDA ban.


Researchers used statistical models to identify factors related to changes in e-cigarette usage behavior. They found a close correlation between using tank system e-cigarettes and switching to other flavors not regulated by the FDA's flavor law enforcement policies.


The use of mint-flavored electronic cigarettes over the past 30 days is associated with switching to mint-flavored electronic cigarettes. Those who reported smoking every day or every few days were more likely to switch to tobacco-flavored electronic cigarettes or combustible tobacco products.


On the other hand, people who use flavored electronic cigarettes without nicotine are more likely to quit smoking. Although the study was not intended to establish a causal relationship, the association supports previous research showing that reducing nicotine levels in cigarettes can help smokers quit. However, further research is needed to better understand the relationship between the use of low-nicotine electronic cigarettes and smoking cessation.


Looking towards the future, Li Dongmei believes that if this policy covers all flavors of electronic cigarettes (including mint and all types of electronic cigarettes) and actively monitors the implementation and compliance of the policy, then the policy may be effective. "Both are important in reducing the popularity of electronic cigarettes among young people in the United States," she said.


2FIRSTS will continue to cover this topic, with updates available on the "2FIRSTS APP". Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds American says nearly 183,000 U.S. retail outlets are under contract, with its Retail Marketing Plan Contract covering about 94% of company volume and requiring point-of-sale age verification. The company combines those contracts with We Card, TruAge, NACS-linked infrastructure and POS integration, while enhanced Vuse Pro retail rules add ID scanning, purchase limits and stronger underage-sales accountability. The initial Vuse Pro rollout targets about 50,000 stores. The system is taking shape as unauthorized vapor products remain dominant in parts of the U.S. market: a 2026 study estimated they accounted for 69.4% of tracked brick-and-mortar e-cigarette dollar sales in December 2025.
Special Report
Oct.15
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
A September online survey commissioned by Japanese smoking-accessories company Lightec found that 49.5% of respondents would consider reducing tobacco use if prices rose further, while 25.1% would consider switching to cheaper brands and 14.5% would consider using or combining alternatives such as vapes and nicotine-free herbal sticks. Another 64.6% expressed some level of interest in such alternatives. The survey covered 1,088 respondents aged 20 to 70 and was conducted by a company that sells NICOLESS nicotine-free vaping and herbal-stick products, meaning its findings should not be treated as representative of Japan's smoking population.
DATA
Oct.12
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia's digital labeling regime for reusable e-cigarettes and similar personal vaping devices entered its first mandatory phase in September 2026. From September 1, manufacturers, importers and other market participants must register with the national Chestny ZNAK tracking system. From December 1, newly manufactured and imported covered devices will be required to carry digital identification codes and be reported as entering circulation. Russia has also issued new operational guidance for imports, marking the transition from a voluntary pilot to phased mandatory implementation.
Sep.15